Mineral and Bone Disorders in Pre-dialysis Chronic Kidney Disease

Article Sidebar

Full Article - PDF Review History
Published Jul 20, 2020
    Page: 11-20

Main Article Content

Deepak Kumar Chitralli
Department of Nephrology and Transplant, Columbia Asia Hospital, Yeshwantpur, Bangalore, India.
Brian Mark Churchill
IQVIA, Etamin, Prestige Tech. park, Kadubeeshanahalli, Bangalore, 560103, India.

Abstract

Chronic kidney disease (CKD) affects 9.1% of the world population (estimated in 2017). The estimates indicate that globally 1.2 million people died of CKD in 2017. As kidney function declines, there is a progressive deterioration in mineral homeostasis. There are changes in circulating levels of hormones as well including parathyroid hormone (PTH), vitamin D, fibroblast growth factor-23 (FGF-23), and growth hormone. Studies have also found association between MBD and fractures, cardiovascular disease (CVD) and mortality.

It is well established that abnormalities in mineral metabolism are apparent early in the course of chronic kidney disease (CKD). This study was undertaken to assess and compare the biochemical markers of bone mineral disorders in diabetics with early CKD and non-diabetics with early CKD.

Keywords:
Mineral and bone disorders, chronic kidney disease, hypocalcemia in CKD, hyperphosphatemia in CKD, alkaline phosphatase in CKD, parathyroid hormone in CKD, vitamin D in CKD.

Article Details

How to Cite
Chitralli, D. K., & Churchill, B. M. (2020). Mineral and Bone Disorders in Pre-dialysis Chronic Kidney Disease. International Journal of Advances in Nephrology Research, 3(1), 11-20. Retrieved from https://journalijanr.com/index.php/IJANR/article/view/30098
Issue
2020 - Volume 3 [Issue 1]
Section
Original Research Article

References

Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: A neglected subgroup. Heart Asia. 2016;8(2):56-61.

Published 2016 Nov 7.

Doi:10.1136/heartasia-2016-010809

Chitralli DK, Churchill BM. Vascular and valvular calcification in diabetic patients with or without CKD. Asian Journal of Research in Nephrology. July; 2020.

Accepted for publication.

Churchill BM, Patri P, Cama R, Inrig JK. TNF-α, TNF Receptors and Their Complex Implications in Therapy. Asian Journal of Immunology, June 2020;4(1),36-50. Available:http://www.journalaji.com/index.php/AJI/article/view/30127. Accessed on 16 June 2020.

Gutie´rrez1 OM, Isakova1 T, Andress DL et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney International. 2008;73:956–962.

Kidney disease improving global outcomes. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney International Supplements. 2017;7(1):1-59.

Patricia Wahl et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patient with chronic kidney disease. Diabetes care.2012;3:1-8.

Lash JP et al. Chronic renal insufficiency cohort (CRIC) study: Baseline characteristics and association with kidney function. Clin J Am Soc Nephrol 2009; 4:1302-1311.

Stephan S, Trivedi K, Kovesdy CP. Association of disorders in mineral metabolism and progression of CKD. Clin J Am Soc Nephrol 2006;1(4):825-831.

Sharon M. Moe et al. Chronic kidney disease – Mineral bone disease. Brenner and Rector’s, The Kidney, 9th Edition. 2015;54:2021-58.

Banerjee S, Singh N, Sharma OP, and Prakash J. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study. Indian J Nephrol. 2012;22(4):285–291.